Bouayad A. Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy. World J Clin Oncol 2025; 16(12): 115789 [DOI: 10.5306/wjco.v16.i12.115789]
Corresponding Author of This Article
Abdellatif Bouayad, MD, Associate Professor, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr
Research Domain of This Article
Immunology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 24, 2025 (publication date) through Dec 29, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Bouayad A. Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy. World J Clin Oncol 2025; 16(12): 115789 [DOI: 10.5306/wjco.v16.i12.115789]
World J Clin Oncol. Dec 24, 2025; 16(12): 115789 Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.115789
Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy
Abdellatif Bouayad
Abdellatif Bouayad, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Oujda-Angad 60049, Oriental, Morocco
Author contributions: Bouayad A wrote, designed, and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdellatif Bouayad, MD, Associate Professor, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr
Received: October 27, 2025 Revised: October 30, 2025 Accepted: November 20, 2025 Published online: December 24, 2025 Processing time: 59 Days and 6.4 Hours
Abstract
Malignant diseases in both children and adults are a worldwide public health priority with a high socioeconomic burden. Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) molecule exhibits divergent expression patterns across different cancers. Its increased expression in some tumors may allow them to escape anti-tumor immune responses, potentially by inducing an immunosuppressive tumor microenvironment and favoring a poorer prognosis. Conversely, in vivo, a mutated ENTPD6 gene may induce effective cytotoxic T cell responses, thereby reducing liver tumor size. Additionally, low expression of ENTPD6 has been related to chemotherapy resistance, whereas specific ENTPD6-derived neoepitopes may potentially enhance the efficacy of immunotherapy. This paper analyses the dual roles and clinical utility of ENTPD6 in cancer.
Core Tip: Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) has dual effects on cancer development and progression, influencing immune surveillance and immune evasion through tumor microenvironment modulation. It serves as a promising novel molecular biomarker for prognosis and for predicting cancer therapy responses. Furthermore, ENTPD6-derived neopeptide vaccines, as well as adoptive T-cell transfer using T cells engineered with T-cell receptors targeting ENTPD6, may constitute promising strategies in cancer immunotherapy.
